Biophytis Reports H1 2021 Financial Results and Provides Business Update - Seite 2

From a financial perspective, our cash position was strengthened following our successful IPO in the US market. We also closed a new ORNANE contract with Atlas up to 32M€ securing the outlook of the Company's financing.”

Income Statement Summary ^(*)

		For the Half Years Ended June 30,
(amounts in thousands of euros, except share data)		2020			2021
Research and development, net of research tax credit		(5,192	)		(7,594	)
General and administrative expenses		(2,269	)		(2,919	)
Operating Loss		(7,461	)		(10,513	)
Net financial expense		(1,999	)		(5,352	)
Loss before taxes		(9,460	)		(15,865	)
Net loss		(9,460	)		(15,865	)
Basic and diluted weighted average number of shares outstanding		37,211,432			110,680,727
Basic and diluted loss per share (€/share)		(0.25	)		(0.14	)

^{(*) the interim 2021 consolidated financial statements were subject to limited review by the Statutory Auditors.}